Conditions: Breast Cancer; Biliary Tract Carcinoma; Ovarian Cancer; Endometrial Cancer; Squamous Non-Small Cell Lung Cancer
Interventions: Drug: AZD8205; Drug: AZD8205 and AZD2936 (Rilvegostomig); Drug: AZD8205 and AZD5305 (saruparib); Drug: AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig); Drug: AZD8205 in combination with AZD9574; Drug: AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)
Sponsors: AstraZeneca
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
